Status:
COMPLETED
Does Mirabegron Increase the Body Heat Generated by the Nervous System
Lead Sponsor:
Christopher Bell
Collaborating Sponsors:
Indiana University
Conditions:
Thermoregulation
Eligibility:
All Genders
18-40 years
Phase:
EARLY_PHASE1
Brief Summary
Acute mirabegron administration has been shown to increase brown fat activity in humans. Long-term mirabegron administration upregulates brown fat, and appears to improve glucose regulation, and chang...
Detailed Description
The Undersea Medicine Program at the Office of Naval Research has invited Indiana University, Rutgers and Colorado State University, to explore the potential of the medication, Mirabegron, to improve ...
Eligibility Criteria
Inclusion
- age 18-40 years,
- regular participation in more than 150 minutes of moderate intensity exercise, every week, during the previous two years.
Exclusion
- History of autonomic, cardio-pulmonary, and/or metabolic disease (including heart failure, hypertension, arrhythmia, vascular disease, and/or diabetes)
- contraindication for mirabegron ingestion, such as previously diagnosed liver and/or kidney dysfunction,
- use of medication that may unfavorably interact with mirabegron, including thioridazine (Mellaril™ and Mellaril-S™), flecainide (Tambocor®), propafenone (Rythmol®), digoxin (Lanoxin®) and solifenacin succinate (VESIcare®)
- pregnancy or breast feeding
- habitual use of tobacco/nicotine products (2 or more uses within the previous month)
- any type of bladder dysfunction, taking medication related to bladder issues, or a history of bladder issues.
- Sulfite Allergy '
Key Trial Info
Start Date :
April 27 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2024
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT06011265
Start Date
April 27 2023
End Date
April 30 2024
Last Update
June 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Colorado State University
Fort Collins, Colorado, United States, 80523